Management of New-Onset Diabetes Mellitus After Transplantation

References

• Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002; 25(3): 583–592.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3(2): 178–185.
   PubMed Web of Science ®Google Scholar
• Kiberd M, Panek R, Kiberd BA. New onset diabetes mellitus post-kidney transplantation. Clin Transplant. 2006; 20(5): 634–639.
   PubMed Web of Science ®Google Scholar
• Sulane E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation. 2005; 80(7): 945–952.
   PubMed Web of Science ®Google Scholar
• Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002; 62(4): 1440–1446.
   PubMed Web of Science ®Google Scholar
• Davidson J, Wilkinson A, Dantal J; International Expert Panel. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003; 75(10): SS3–SS24.
   Google Scholar
• Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65(3): 380–384.
   PubMed Web of Science ®Google Scholar
• Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005; 19(3): 291–298.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008; 31(suppl 1): s12–s14.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109(3): 433–438.
   PubMed Web of Science ®Google Scholar
• David DS, Cheigh JS, Braun DW Jr, Fotino M, Stenzel KH, Rubin AL. HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA. 1980; 243(6): 532–533.
   PubMed Web of Science ®Google Scholar
• Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era—an analysis of risk factors. Transplantation. 1991; 51(2): 343–347.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29(8): 1963–1972.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Davidson JA, Blonde L; ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 2007; 13(2): 260–268.
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31(1): 173–175.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care. 2008; 31(suppl 1): s16–s27.
   Google Scholar
• Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrøm J, Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant. 2001; 16(4): 829–835.
   PubMed Web of Science ®Google Scholar
• Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003; 3(5): 590–598.
   PubMed Web of Science ®Google Scholar
• Wyzgal J, Oldakowska-Jedynak U, Paczek L, et al. Posttransplantation diabetes mellitus under calcineurin inhibitor. Transplant Proc. 2003; 35(6): 2216–2218.
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes. Diabetes Care. 2005; 28(2): 260–265.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005; 23(1): 78–86.
   Google Scholar
• Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004; 70(3): 489–500.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11): 3080–3086.
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007; 147(6): 386–399.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131(4): 281–303.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24): 2457–2471.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279–1289.
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA. 2007; 298(2): 194–106.
   PubMed Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care. 2003; 26(6): 784–790.
   PubMed Web of Science ®Google Scholar